University of Khartoum Graduate College Medical and Health Studies Board

Total Page:16

File Type:pdf, Size:1020Kb

University of Khartoum Graduate College Medical and Health Studies Board University of Khartoum Graduate College Medical and Health Studies Board Pathophysiology of Severe Malaria in Children: Clinical and Laboratory Correlations A thesis submitted for the degree of Ph. D in Human Physiology By Nisreen Daffalla Omer Haj Edris M.B.B.S Supervisor Professor Mohammed Yousif Sukkar M.B.B.S, Ph. D in Human Physiology 2010 Table of contents Dedication I Acknowledgements II Abbreviations III Abstract IV-VI Arabic abstract VII-IX List of figures X List of tables XI CHAPTER ONE: INTRODUCTION & LITERATURE REVIEW & OBJECTIVES OF THE STUDY Introduction 1-3 Malaria parasite life cycle 4 Clinical presentation of malaria 5 Uncomplicated malaria 6 Severe malaria 6 Pathophysiology of severe malaria 7 Overview of immunity and cytokines in malaria 7 Cytokines members: Interleukins 8-9 IL-10 10 Chemokines 11 Interferons 12 Tumor necrosis factor-alpha 12-14 General properties of cytokines receptors 14 Effect of cytokines on the immune system 14-15 Cytokines and immunity in malaria 15-17 Innate immunity 17-19 The role of nitric oxide in malaria 19-20 Adaptive immunity 20-21 Cytokines in the immunopathology of malaria 22 Serious complications of malaria 23 Cerebral malaria 23-29 Repeated convulsions 29 Severe anaemia 30-34 Hypoglycemia 34-37 Renal involvement in malaria 37-39 Electrolyte changes 39-41 Haemoglobinuria 42-43 Objectives 44 CHAPTER TWO: PATIENTS AND METHODS Location and time of the study 45 Patients and control 45 History and physical examination 45 Malaria diagnosis and blood tests 45 Blood samples 45 Malaria diagnosis and parasitemia estimation 46 Haemoglobin estimation 46 Total white blood cells count 47 Random blood glucose measurement 47 Hormone assays; insulin and C-peptide measurement 47-49 Urea measurement 49 Creatinine measurement 49 Sodium and potassium measurement 50 Bilirubin measurement 50 Alanine aminotransferase measurement 51 Aspartate aminotransferase measurement 52 Alkaline phosphatase measurement 52 Cytokines measurement 53 IFN-γ assay 53 TNF-α assay 54 IL-10 assay 54 Stastical methods 55 CHAPTER THREE: RESULTS Sample characteristics 56 Clinical presentation 57 Blood glucose 58 Insulin 59 C- peptide 60 Insulin: C-peptide ratio 61 Correlation between insulin and blood glucose 62 Correlation between insulin and C-peptide 63 Haemoglobin 64 Total white blood cells count 65 Bilirubin 66 Liver enzymes 67-70 Urea 70 Creatinine 71 Sodium 72-73 Potassium 74 Association of the course of malaria and the clinical categories 75 Mixed presentation 75 Cerebral malaria 76 Parasitemia 76-79 Period of illness 79 TNF-α 80-82 IFN-γ 83-87 IL-10 87-89 Correlation of cytokines with age 90-91 CHAPTER FOUR: DISCUSSION Introduction 92 Effect of age on the severity of malaria 92-93 Anaemia in severe malaria 94-96 Liver involvement in severe malaria 96-99 Spleen in severe malaria 99-101 TWBCs 101 Blood glucose homeostasis 102-106 Insulin and C-peptide 106-101 Disturbances of electrolytes and renal functions 107-111 Sodium 107 Potassium 108 Urea 109 Creatinine 110 Haemoglobinuria 111 Cytokines in severe malaria 112-114 TNF-α 114-117 IL-10 117-121 IFN-γ 121-125 Genetic profile 125 Cerebral malaria 126-129 Repeated convulsions 130 Indicators of poor outcome 131-134 Conclusions 135-139 Recommendations 140 References 141-188 Appendix 189-191 Dedication I dedicate this work to my parents, my sisters, my husband and to my children Mohammed and Abdelrahman. I Acknowledgments I wish to express my deep gratitude and special thanks to Professor Mohammed Yousif Sukkar, Department of Physiology, Faculty of Medicine, University of Khartoum and Nile College, for his unlimited supervision, encouragement and moral support. His scholastic approach, clear conception and insight of the problem have opened a new vista which profoundly enlightened my knowledge and helped me to understand the complicated issues. Also he has been very kind in checking the script of the thesis, Iam very grateful to Dr. Abdelsalam Alnoor, Dr.Amal Saeed and Professor. Ammar Eltahir, Department of Physiology, Faculty of Medicine, University of Khartoum for their unlimited support and encouragement. I would like to thank those volunteers who provided blood samples for the study. I am obliged to Wadmedani Paediatric Hospital main laboratory staff for their cooperation and their help with the laboratory analysis. My special thanks go to the International laboratory staff for their kind support and help with the cytokines measurement. I wish to thank Adil Amin for his help with the stastical analysis. My sincere thanks are also due to my parents, sisters, brothers and my husband for their patience, support and continued encouragement which kept the momentum of my research going. II Abbreviations SM: Severe malaria UM: Uncomplicated malaria CM: Cerebral malaria SA: Severe anaemia NO: Nitric oxide RBCs: Red blood cells Hb: Haemoglobin RBG: Random blood glucose I: C: Insulin C-peptide ratio TWBCs: Total white blood cells III ABSTRACT Background Despite the programmes of malaria control the incidence of mortality from severe malaria (SM) continues to rise. This is mainly attributable to the fact that the pathophysiological mechanisms are still not clearly defined. Objectives This project investigated the endocrine and paracrine aspects of the pathophysiology of SM in children. The study monitored relevant clinical and laboratory parameters of SM cases on admission so as to identify and correct life threatening changes. Patients and Methods This is a cross sectional study conducted at Wadmedani Paediatric Hospital from September 2007 to September 2008. Fifty six Children with SM, identified according to WHO criteria, were included in the study. Thirty one children with uncomplicated malaria (UM) were included for comparison. Both groups underwent a history and physical examination. Investigations included: parasitemia, Hb, RBG, TWBC, liver enzymes, bilirubin, urea, creatinine, sodium, potassium and cytokines (TNF-α, IFN-γ, IL-10). Statistical analysis was carried out with SPSS for windows. Means were analyzed by student’s T test. Correlations were analyzed using χ2 tests, Pearson's correlation coefficient and Spearman' rank correlation coefficient tests. Assessments of prognostic factors were conducted with regression model. P values < 0.05 were considered significant. Results Children with SM were younger than those with UM (mean age=56.75 months compared to 82.71 months, P value= 0.001). IV A significant difference was found in the mean RBG between children with SM and UM (89.27±39.06 compared to 108.06±39.14 mg/dl respectively) P value= 0.035 as well as in the mean Hb (7.54±2.71 compared to 9.91±1.67 mg/dl respectively, P value= 0.000). The pattern and cytokines secretion levels showed higher mean TNF-α in children below 5 years old and in children with CM. Those above 5 years had higher IFN-γ which was found to correlate positively with Hb, RBG, splenomegaly and hepatomegaly. Children with SA had a lower IFN-γ and IL-10 when compared to UM. Conclusions SA may result from haemolysis of red blood cells, low level of IFN-γ and IL-10. Glucose consumption by the parasites and low IFN-γ may be the causes of hypoglycemia. CM, mixed presentation, young age and hyperkalaemia were independently associated with increased risk of morbidity and mortality. High bilirubin, high TWBCs counts, high urea, high creatinine, low Hb and low RBG were significantly associated with CM and mixed presentation. V ﻣﻠﺨﺺ اﻟﺪراﺳﺔ ﺧﻠﻔﻴﺔ ﻋﻠﻲ اﻟﺮﻏﻢ ﻣﻦ ﺑﺮاﻣﺞ ﻣﻜﺎﻓﺤﺔ اﻟﻤﻼرﻳﺎ اﻻ ان ﻣﻌﺪل اﻟﻮﻓﻴﺎت ﻣﺎزاﻟﺖ ﻓﻲ ارﺗﻔﺎع ﻣﺴﺘﻤﺮ. وهﺬا ﻳﻌﺰي اﺳﺎﺳﺎ اﻟﻲ ﺣﻘﻴﻘﺔ ان اَﻟﻴﺎت اﻟﻔﺴﻴﻮﻟﻮﺟﻴﺎ اﻟﻤﺮﺿﻴﺔ ﻻﺗﺰال ﻏﻴﺮ ﻣﻌﺮوﻓﺔ اﻻهﺪاف هﺬﻩ اﻟﺪراﺳﺔ ﺗﺒﺤﺚ ﻓﻲ اﻟﻔﺴﻴﻮﻟﻮﺟﻴﺎ اﻟﻤﺮﺿﻴﺔ ﻟﻠﻤﻼرﻳﺎ اﻟﻮﺧﻴﻤﺔ. ﺗﺮﺻﺪ هﺬﻩ اﻟﺪراﺳﺔ اﻟﻤﺆﺷﺮات اﻟﺴﺮﻳﺮﻳﺔ واﻟﻤﻌﻠﻤﻴﺔ ﺧﻼل اﻟﻤﺮاﺣﻞ اﻟﻤﺒﻜﺮة ﻟﻠﻤﺮض وذﻟﻚ ﻟﺘﺤﺪﻳﺪ وﺗﺼﺤﻴﺢ اﻟﺘﻐﻴﻴﺮات اﻟﺘﻲ ﺗﻬﺪد اﻟﺤﻴﺎة. اﻟﻤﺮﺿﻲ واﻟﻮﺳﺎﺋﻞ: ﻳﻘﻮم هﺬا اﻟﺒﺤﺚ ﻋﻠﻲ دراﺳﺔ ﻣﻘﻄﻌﻴﺔ ﻋﻠﻲ ﻣﺠﻤﻮﻋﺔ ﻣﻦ اﻟﻤﺮﺿﻲ. اﺟﺮﻳﺖ هﺬﻩ اﻟﺪراﺳﺔ ﻓﻲ ﻣﺴﺘﺸﻔﻲ ودﻣﺪﻧﻲ ﻟﻼﻃﻔﺎل ﻓﻲ اﻟﻔﺘﺮة ﻣﻦ ﺳﺒﺘﻤﺒﺮ 2007 ﺣﺘﻲ ﺳﺒﺘﻤﺒﺮ2008. ﺷﻤﻠﺖ اﻟﺪراﺳﺔ 56 ﻃﻔﻞ ﻳﻌﺎﻧﻮن ﻣﻦ اﻟﻤﻼرﻳﺎ اﻟﻮﺧﻴﻤﺔ وﻗﺪ ﺗﻢ ﺗﺤﺪﻳﺪهﻢ وﻓﻘﺎ ﻟﻤﻌﺎﻳﻴﺮ ﻣﻨﻈﻤﺔ اﻟﺼﺤﺔ اﻟﻌﺎﻟﻤﻴﺔ. ﺷﻤﻠﺖ اﻟﺪراﺳﻪ ا ﻳ ﻀ ﺎ31ُ ﻃﻔﻞ ﻣﻦ اﻟﺬﻳﻦ ﻳﻌﺎﻧﻮن ﻣﻦ اﻟﻤﻼرﻳﺎ ﻏﻴﺮ اﻟﻮﺧﻴﻤﺔ آﻠﺘﺎ اﻟﻤﺠﻤﻮﻋﺘﻴﻦ ﺧﻀﻌﺖ ﻟﻠﻔﺤﺺ اﻟﺴﺮﻳﺮي واﻻﺧﺘﺒﺎرات اﻟﻤﻌﻤﻠﻴﻪ اﻟﺘﺎﻟﻴﺔ: ﻣﻌﺪل ﺗﻮاﺟﺪ اﻟﻄﻔﻴﻞ، اﻟﻬﻴﻤﻮﻏﻠﻮﺑﻴﻦ، ﻋﺪد آﺮﻳﺎت اﻟﺪم اﻟﺒﻴﻀﺎء ، اﻧﺰﻳﻤﺎت اﻟﻜﺒﺪ، اﻟﺒﻴﻠﻮروﺑﻴﻦ ، اﻟﺒﻮﻟﻴﻨﺎ ، اﻟﻜﺮﻳﺎﺗﻴﻨﻴﻦ ، اﻟﺼﻮدﻳﻢ ، اﻟﺒﻮﺗﺎﺳﻴﻮم و اﻟﺴﺎﻳﺘﻮآﺎﻳﻨﺎت اﻻﺗﻴﻪ (TNF-α, IFN-γ, IL-10). اﺳﺘﺨﺪم SPSS ﻟﻠﺘﺤﻠﻴﻞ اﻻﺣﺼﺎﺋﻰ. ﻗﻮرﻧﺖ اﻟﻤﺘﻮﺳﻄﺎت ﺑﺎﺧﺘﺒﺎر student’s T test. ﻟﺘﺤﻠﻴﻞ اﻻرﺗﺒﺎﻃﺎت اﺳﺘﺨﺪﻣﺖ اﻻﺧﺘﺒﺎرات اﻻﺗﻴﻪχ2 tests و Pearson's correlation coefficient and Spearman' rank correlation coefficient tests. ﺗﻘﻴﻴﻢ اﻟﻌﻮاﻣﻞ اﻟﺘﻨﺒﺆﻳﻪ اﺟﺮى ﺑﻮاﺳﻄﺔ regression model. ﻗﻴﻤﺔ P اﻗﻞ ﻣﻦ 0.05 اﻋﺘﺒﺮت ﻓﺮق ﻣﻌﻨﻮى. اﻟﻨﺘﺎﺋﺞ: اﻻﻃﻔﺎل اﻟﻤﺼﺎﺑﻮن ﺑﺎﻟﻤﻼرﻳﺎ اﻟﻮﺧﻴﻤﺔ آﺎﻧﻮا ﻣﻦ ذوي اﻻﻋﻤﺎر اﻟﺼﻐﻴﺮة ﻣﻘﺎرﻧﺔ ﺑﻤﺮﺿﻲ اﻟﻤﻼرﻳﺎ ﻏﻴﺮ اﻟﻮﺧﻴﻤﺔ (ﻣﺘﻮﺳﻂ اﻟﻌﻤﺮ75.56 ﺷﻬﺮﻣﻘﺎرﻧﻪ 82.71 ﺷﻬﺮ) ﻗﻴﻤﺔ P=0.001 وﺟﺪ ﻓﺮق ﻣﻌﻨﻮي ﻓﻲ ﻣﺴﺘﻮي اﻟﺠﻠﻜﻮز ﻓﻲ اﻟﺪم ﺑﻴﻦ ﻣﺮﺿﻲ اﻟﻤﻼرﻳﺎ اﻟﻮﺧﻴﻤﺔ وﻏﻴﺮ اﻟﻮﺧﻴﻤﺔ (89.27±39.06 - 108.6±39.14 ﻣﻠﺠﻢ/ دﺳﻠﺘﺮ ﻋﻠﻲ اﻟﺘﻮاﻟﻲ) ﻗﻴﻤﺔ P=0.035 آﺬاﻟﻚ ﻓﻰ اﻟﻬﻴﻤﻮﻏﻠﻮﺑﻴﻦ (7.54±2.71ﻣﻠﺠﻢ/ دﺳﻠﺘﺮ -9.91±1.67 ﻣﻠﺠﻢ/ دﺳﻠﺘﺮ ﻋﻠﻲ اﻟﺘﻮاﻟﻲ) ﻗﻴﻤﺔ P=0.000. VI اﻻﻃﻔﺎل دون ﺳﻦ اﻟﺨﺎﻣﺴﺔ ارﺗﻔﻊ ﻟﺪﻳﻬﻢ TNF-α آﻤﺎ ارﺗﻔﻊ ﻋﻨﺪ ﻣﺮﺿﻲ اﻟﻤﻼرﻳﺎ اﻟﺪﻣﺎﻏﻴﺔ. اﻻﻃﻔﺎل ﻓﻮق ﺳﻦ اﻟﺨﺎﻣﺴﺔ ارﺗﻔﻊ ﻟﺪﻳﻬﻢ IFN-γ اﻟﺬى وﺟﺪ اﻧﻪ ﻳﺮﺗﺒﻂ ارﺗﺒﺎط اﻳﺠﺎﺑﻲ ﻣﻊ اﻟﻬﻴﻤﻮﻏﻠﻮﺑﻴﻦ ، اﻟﺠﻠﻜﻮز، ﺗﻀﺨﻢ اﻟﻄﻮﺣﺎل وﺗﻀﺨﻢ اﻟﻜﺒﺪ. ﻣﺮﺿﻲ ﻓﻘﺮ اﻟﺪم اﻟﺤﺎد ﻧﻘﺺ ﻋﻨﺪهﻢ ﻣﺴﺘﻮي IFN-γ و-IL 10 اآﺜﺮ ﻋﻨﺪ اﻟﻤﻘﺎرﻧﺔ ﺑﻤﺮﺿﻲ اﻟﻤﻼرﻳﺎ ﻏﻴﺮ اﻟﻮﺧﻴﻤﺔ و اﻟﺬﻳﻦ ﻻﻳﻌﺎﻧﻮن ﻣﻦ ﻓﻘﺮ اﻟﺪم اﻟﺤﺎد. اﻟﺨﻼﺻﻪ ﻓﻘﺮ اﻟﺪم اﻟﺤﺎد ﻳﻨﺘﺞ ﻋﻦ ﺗﻜﺴﺮ آﺮﻳﺎت اﻟﺪم اﻟﺤﻤﺮاء، ﺗﺜﺒﻴﻂ ﻋﻤﻠﻴﺔ ﺗﺼﻨﻴﻊ آﺮﻳﺎت اﻟﺪم اﻟﺤﻤﺮاء وﻧﻘﺺ ﻣﺴﺘﻮى IFN-γ و IL-10 . إﻧﺨﻔﺎض اﻟﺠﻠﻜﻮز اﻟﺤﺎد رﺑﻤﺎ ﻳﻨﺘﺞ ﻋﻦ إﺳﺘﻬﻼك اﻟﻄﻔﻴﻞ اﻟﻤﺒﺎﺷﺮ ﻟﻠﺠﻠﻜﻮز واﻧﺨﻔﺎض اﻟﺴﺎﻳﺘﻮآﺎﻳﻦ IFN-γ اﻟﻤﻼرﻳﺎ اﻟﺪﻣﺎﻏﻴﻪ، اﻟﻤﻀﺎﻋﻔﺎت اﻟﻤﺘﻌﺪدﻩ، اﻟﻌﻤﺮ اﻟﺼﻐﻴﺮ وإرﺗﻔﺎع اﻟﺒﻮﺗﺎﺳﻴﻮم ﻓﻰ اﻟﺪم ﻟﺪﻳﻬﺎ إرﺗﺒﺎط ﺑﺰﻳﺎدﻩ ﻣﻀﺎﻋﻔﺎت ووﻓﻴﺎت اﻟﻤﻼرﻳﺎ. إرﺗﻔﺎع اﻟﺒﻴﻠﻮروﺑﻴﻦ، إرﺗﻔﺎع ﻋﺪد آﺮﻳﺎت اﻟﺪم اﻟﺒﻴﻀﺎء، إرﺗﻔﺎع اﻟﺒﻮﻟﻴﻨﺎ، إرﺗﻔﺎع اﻟﻜﺮﻳﺎﺗﻨﻴﻦ، اﻧﺨﻔﺎض اﻟﻬﻴﻤﻮﻏﻠﻮﺑﻴﻦ واﻧﺨﻔﺎض اﻟﺠﻠﻜﻮز ارﺗﺒﻄﺖ ﻣﻌﻨﻮﻳﺎ ﺑﺎﻟﻤﻼرﻳﺎ اﻟﺪﻣﺎﻏﻴﻪ و اﻟﻤﻀﺎﻋﻔﺎت اﻟﻤﺘﻌﺪدﻩ.
Recommended publications
  • Correlation of Cytokine Level with the Severity of Severe Fever With
    Liu et al. Virology Journal (2017) 14:6 DOI 10.1186/s12985-016-0677-1 RESEARCH Open Access Correlation of cytokine level with the severity of severe fever with thrombocytopenia syndrome Miao-Miao Liu1, Xiao-Ying Lei1, Hao Yu2, Jian-zhi Zhang3 and Xue-jie Yu1,4* Abstract Background: Severe fever with thrombocytopenia syndrome (SFTS) was an emerging hemorrhagic fever that was caused by a tick-borne bunyavirus, SFTSV. Although SFTSV nonstructural protein can inhibit type I interferon (IFN-I) production Ex Vivo and IFN-I played key role in resistance SFTSV infection in animal model, the role of IFN-I in patients is not investigated. Methods: We have assayed the concentration of IFN-α, a subtype of IFN-I as well as other cytokines in the sera of SFTS patients and the healthy population with CBA (Cytometric bead array) assay. Results: The results showed that IFN-α, tumor necrosis factor (TNF-α), granulocyte colony-stimulating factor (G-CSF), interferon-γ (IFN-γ), macrophage inflammatory protein (MIP-1α), interleukin-6 (IL-6), IL-10, interferon-inducible protein (IP-10), monocyte chemoattractant protein (MCP-1) were significantly higher in SFTS patients than in healthy persons (p < 0.05); the concentrations of IFN-α, IFN-γ, G-CSF, MIP-1α, IL-6, and IP-10 were significant higher in severe SFTS patients than in mild SFTS patients (p < 0.05). Conclusion: The concentration of IFN-α as well as other cytokines (IFN-γ, G-CSF, MIP-1α, IL-6, and IP-10) is correlated with the severity of SFTS, suggesting that type I interferon may not be significant in resistance SFTSV infection in humans and it may play an import role in cytokine storm.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0367695A1 Wilson Et Al
    US 20160367695A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0367695A1 Wilson et al. (43) Pub. Date: Dec. 22, 2016 (54) POLYPEPTIDE CONSTRUCTS AND USES (30) Foreign Application Priority Data THEREOF Oct. 28, 2011 (AU) ................................ 2011 9045O2 (71) Applicant: Teva Pharmaceuticals Australia Pty Ltd, Macquarie Park (AU) Publication Classification (72) Inventors: David S. Wilson, Freemont, CA (US); Sarah L. Pogue, Freemont, CA (US); (51) Int. Cl. Glen E. Mikesell, Pacifica, CA (US); A6II 47/48 (2006.01) Tetsuya Taura, Palo Alto, CA (US); C07K 6/28 (2006.01) Wouter Korver, Mountain View, CA (52) U.S. Cl. (US); Anthony G. Doyle, Drummoyne CPC ..... A61K 47/48269 (2013.01); C07K 16/2896 (AU); Adam Clarke, Five Dock (AU); (2013.01); C07K 231 7/565 (2013.01); C07K Matthew Pollard, Dural (AU): 2317/55 (2013.01); C07K 2317/92 (2013.01) Stephen Tran, Strathfield South (AU); Jack Tzu Chiao Lin, Redwood City, (57) ABSTRACT CA (US) (21) Appl. No.: 15/194,926 The present invention provides a polypeptide construct (22) Filed: Jun. 28, 2016 comprising a peptide or polypeptide signaling ligand linked to an antibody or antigen binding portion thereof which Related U.S. Application Data binds to a cell Surface-associated antigen, wherein the ligand (63) Continuation of application No. 14/262,841, filed on comprises at least one amino acid Substitution or deletion Apr. 28, 2014, which is a continuation of application which reduces its potency on cells lacking expression of said No. PCT/AU2012/001323, filed on Oct. 29, 2012. antigen. Patent Application Publication Dec.
    [Show full text]
  • WO 2010/142017 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 16 December 2010 (16.12.2010) WO 2010/142017 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 48/00 (2006.01) A61P 37/04 (2006.01) kind of national protection available): AE, AG, AL, AM, A61P 31/00 (2006.01) A61K 38/21 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) Number: International Application DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/CA20 10/000844 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 8 June 2010 (08.06.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/185,261 9 June 2009 (09.06.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, (71) Applicant (for all designated States except US): DE- ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, FYRUS, INC .
    [Show full text]
  • ( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0331966 A1 STOVER Et Al
    US 20200331966A1 IN ( 19 ) United States ( 12 ) Patent Application Publication ( 10 ) Pub . No .: US 2020/0331966 A1 STOVER et al . ( 43 ) Pub . Date : Oct. 22 , 2020 ( 54 ) FUSION PROTEIN COMPOSITION ( S ) Related U.S. Application Data COMPRISING MASKED TYPE I INTERFERONS ( IFNA AND IFNB ) FOR USE ( 60 ) Provisional application No. 62 / 920,140 , filed on Apr. IN THE TREATMENT OF CANCER AND 15 , 2019 . METHODS THEREOF Publication Classification ( 71 ) Applicant: Qwixel Therapeutics, Los Angeles, CA ( 51 ) Int. Ci . ( US ) CO7K 7/08 ( 2006.01 ) A61K 47/65 ( 2006.01 ) ( 72 ) Inventors : David STOVER , Encino, CA (US ) ; A61P 35/00 ( 2006.01 ) Sherie MORRISON , Los Angeles, CA ( 52 ) U.S. CI . ( US ) ; Alex VASUTHASAWAT , Los CPC CO7K 7/08 ( 2013.01 ) ; A61K 38/00 Angeles , CA ( US ) ; Kham TRINH , ( 2013.01 ) ; A61P 35/00 ( 2018.01 ) ; A61K 47/65 Porter Ranch , CA ( US ) ; George ( 2017.08 ) AYOUB , Los Angeles, CA ( US ) ( 57 ) ABSTRACT Fusion Protein compositions comprising masked IFNs and ( 73 ) Assignee : Qwixel Therapeutics, Los Angeles, CA methods of making masked IFNs are disclosed herein . ( US ) Consequently, the masked IFNs can be fused to a Mab or binding fragment thereof and be administered to patients as ( 21 ) Appl. No .: 16 /849,889 a therapeutic modality and provide a method of treating cancer, immunological disorders and other disease . ( 22 ) Filed : Apr. 15 , 2020 Specification includes a Sequence Listing . Matripase ST 14 Cleaves an IFN Mask from the Heavy Chain of an anti CD138 Fusion Ab . 1 2 3 1. ant - CD138 / Na 2. anti - C0138 IFNa mask 3. anti - C0138 FNa mask w / MST14 Patent Application Publication Oct.
    [Show full text]
  • United States Patent (10) Patent No.: US 9,464,124 B2 Bancel Et Al
    USOO9464124B2 (12) United States Patent (10) Patent No.: US 9,464,124 B2 Bancel et al. (45) Date of Patent: Oct. 11, 2016 (54) ENGINEERED NUCLEIC ACIDS AND 4,500,707 A 2f1985 Caruthers et al. METHODS OF USE THEREOF 4,579,849 A 4, 1986 MacCoSS et al. 4,588,585 A 5/1986 Mark et al. 4,668,777 A 5, 1987 Caruthers et al. (71) Applicant: Moderna Therapeutics, Inc., 4,737.462 A 4, 1988 Mark et al. Cambridge, MA (US) 4,816,567 A 3/1989 Cabilly et al. 4,879, 111 A 11/1989 Chong (72) Inventors: Stephane Bancel, Cambridge, MA 4,957,735 A 9/1990 Huang (US); Jason P. Schrum, Philadelphia, 4.959,314 A 9, 1990 Mark et al. 4,973,679 A 11/1990 Caruthers et al. PA (US); Alexander Aristarkhov, 5.012.818 A 5/1991 Joishy Chestnut Hill, MA (US) 5,017,691 A 5/1991 Lee et al. 5,021,335 A 6, 1991 Tecott et al. (73) Assignee: Moderna Therapeutics, Inc., 5,036,006 A 7, 1991 Sanford et al. Cambridge, MA (US) 9. A 228 at al. J. J. W. OS a 5,130,238 A 7, 1992 Malek et al. (*) Notice: Subject to any disclaimer, the term of this 5,132,418 A 7, 1992 °N, al. patent is extended or adjusted under 35 5,153,319 A 10, 1992 Caruthers et al. U.S.C. 154(b) by 0 days. 5,168,038 A 12/1992 Tecott et al. 5,169,766 A 12/1992 Schuster et al.
    [Show full text]
  • W O 2014/151535 a L 2 5 September 2014 (25.09.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2014/151535 A l 2 5 September 2014 (25.09.2014) P O P C T (51) International Patent Classification: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, C07K 14/705 (2006.01) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/US20 14/025940 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 13 March 2014 (13.03.2014) ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 61/791,537 15 March 2013 (15.03.2013) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 61/787,753 15 March 2013 (15.03.2013) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (71) Applicant: BAYER HEALTHCARE LLC [US/US]; 555 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, White Plains Rd., Tarrytown, NY 10591 (US).
    [Show full text]
  • Severe Sepsis Epidemiology and Sex-Related Differences in Inflammatory Markers
    UMEÅ UNIVERSITY MEDICAL DISSERTATIONS NEW SERIES NO. 1680 ISSN 0346-6612 ISBN: 978-91-7601-149-2 From the Department of Surgical and Perioperative Sciences Anesthesiology and Intensive Care Medicine Umeå University, Sweden Severe sepsis Epidemiology and sex-related differences in inflammatory markers. Sofie Jacobson Fakultetsopponent: Professor Else Tönnesen Dept. of Clinical Medicine - Anaesthesiology Århus, Danmark Umeå 2014 Cover illustration: "First line of defence" Anders Jacobsson Copyright © 2014 Sofie Jacobson ISBN: 978-91-7601-149-2 NEW SERIES NO. 1680 ISSN 0346-6612 Layout and printed by: Print & Media Umeå, Sweden 2014 To my family A goal is a dream with a deadline. ~ Napolean Hill Contents CONTENTS ABSTRACT......................................................................................................................... iv Svensk sammanfattning .........................................................................................................v Abbreviations..................................................................................................................... viii ORIGINAL PAPERS............................................................................................................x PROLOGUE ........................................................................................................................xi INTRODUCTION..................................................................................................................1 Epidemiology ....................................................................................................................2
    [Show full text]
  • Hepatitis C Virus and Interferon Type
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector REVIEW 10.1111/1469-0691.12797 Hepatitis C virus and interferon type III (interferon-k3/interleukin-28B and interferon-k4): genetic basis of susceptibility to infection and response to antiviral treatment E. Riva1, C. Scagnolari2, O. Turriziani2 and G. Antonelli2 1) Department of Integrated Research, Virology Section, University Campus Bio-Medico of Rome and 2) Department of Molecular Medicine, Virology Section, Sapienza University of Rome, Rome, Italy Abstract There has been a significant increase in our understanding of the host genetic determinants of susceptibility to viral infections in recent years. Recently, two single-nucleotide polymorphisms (SNPs), rs12979860 T/C and rs8099917 T/G, upstream of the interleukin (IL)-28B/interferon (IFN)-k3 gene have been clearly associated with spontaneous and treatment-induced viral clearance in hepatitis C virus (HCV) infection. Because of their power in predicting the response to IFN/ribavirin therapy, the above SNPs have been used as a diagnostic tool, even though their relevance in the management of HCV infection will be blunt in the era of IFN-free regimens. The recent discovery of a new genetic variant, ss469415590 TT/DG, upstream of the IL-28B gene, which generates the novel IFN-k4 protein, has opened up a new and alternative scenario to understand the functional architecture of type III IFN genomic regions and to improve our knowledge of the pathogenetic mechanism of HCV infection. A role of ss469415590 in predicting responsiveness to antiviral therapy has also been observed in HCV-infected patients receiving direct antiviral agents.
    [Show full text]
  • Patent Application Publication Oo) Pub. No.: US 2013/0260367 Al Lowery, JR
    US 20130260367A1 (19) United States (12) Patent Application Publication oo) Pub. No.: US 2013/0260367 Al Lowery, JR. et al. (43) Pub. Date: Oct. 3,2013 (54) NMR SYSTEMS AND METHODS FOR THE (86) PCTNo.: PCT/US11/56936 RAPID DETECTION OF ANALYTES § 371 (c)(1), (2), (4) Date: Jun. 20, 2013 Related U.S. Application Data (75) Inventors: Thomas Jay Lowery, JR., Belmont, MA (US); Mark John Audeh, Brighton, (60) Provisional application No. 61/414,141, filed onNov. 16, 2010, provisional application No. 61/418,465, MA (US); Matthew Blanco, Boston, filed on Dec. I, 2010, provisional application No. MA (US); James Franklin Chepin, 61/497,374, filed on Jun. 15,2011. Arlington, MA (US); Vasiliki Demas, Arlington, MA (US); Rahul Dhanda, (30) Foreign Application Priority Data Needham, MA (US); Marilyn Lee Fritzemeier, Lexington, MA (US); Isaac Oct. 22, 2010 (US) .................................... 12/910594 Koh, Arlington, MA (US); Sonia Publication Classification Kumar, Cambridge, MA (US); Lori (51) Int. Cl. Anne Neely, Reading, MA (US); Brian GOlN 33/543 (2006.01) Mozeleski, Knox, ME (US); Daniella C12Q1/70 (2006.01) Lynn Plourde, Arlington, MA (US); GOlN 33/94 (2006.01) Charles William Rittershaus, Malden, C12Q1/68 (2006.01) MA (US); Parris Wellman, Reading, (52) U.S. Cl. MA (US) CPC ........ GOlN33/54326 (2013.01); C12Q1/6825 (2013.01); C12Q1/70 (2013.01); GOlN 33/9493 (2013.01); C12Q1/6895 (2013.01) USPC . 435/5; 436/501; 435/7.1; 435/6.11; 435/7.4; (73) Assignee: T2 Biosystems, Inc., Lexington, MA 435/287.2; 422/69; 422/554 (US) (57) ABSTRACT (21) Appl.
    [Show full text]
  • WO 2013/126803 Al 29 August 2013 (29.08.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/126803 Al 29 August 2013 (29.08.2013) P O P C T (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C07C 271/20 (2006.01) C07C 229/12 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, C07C 217/08 (2006.01) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (21) International Application Number: NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, PCT/US20 13/027469 RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (22) International Filing Date: TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, 22 February 2013 (22.02.2013) ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (30) Priority Data: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 61/602,990 24 February 2012 (24.02.2012) US TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (71) Applicant: PROTIVA BIOTHERAPEUTICS INC. MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, [CA/CA]; 100-8900 Glenlyon Parkway, Burnaby, British TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, Columbia V5 5J8 (CA).
    [Show full text]
  • WO 2013/179143 A2 5 December 2013 (05.12.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/179143 A2 5 December 2013 (05.12.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61M 1/36 (2006.01) A61K 38/19 (2006.01) kind of national protection available): AE, AG, AL, AM, C07K 16/28 (2006.01) A61M 1/34 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61P 35/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, PCT/IB2013/001583 KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 3 1 May 2013 (3 1.05.2013) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, PCT/EP20 12/002340 1 June 2012 (01 .06.2012) EP GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, 12196527.
    [Show full text]
  • United States Patent (10) Patent No.: US 9,624,276 B2 Young Et Al
    USOO9624276B2 (12) United States Patent (10) Patent No.: US 9,624,276 B2 Young et al. (45) Date of Patent: Apr. 18, 2017 (54) PEPTIDIC CHIMERIC ANTIGEN RECEPTOR 7,258,986 B2 8/2007 Maur et al. T CELL, SWITCHES AND USES THEREOF 7,446,190 B2 11/2008 Sadelain et al. 7,514,537 B2 4/2009 Jensen 8,802.374 B2 8, 2014 Jensen (71) Applicant: The California Institute for 8,916,381 B1 12/2014 June et al. Biomedical Research, La Jolla, CA 2004/0044177 A1 3/2004 Macke et al. (US) 2004f0072299 A1* 4, 2004 Gillies ................. A61K 38, 193 435/695 (72) Inventors: Travis Young, La Jolla, CA (US); 2839; ;: A. 258 at al. Chanhyuk Kim, San Diego, CA (US); ck ooper et al. Peter G. Schultz, La Jolla, CA (US) 2006/0083683 A1* 4/2006 HSei ................... Aikip3. 2007/01725.04 A1 7/2007 Shirwan et al. (73) Assignee: The California Institute for 2008/0260731 A1* 10, 2008 Bernett .............. CO7K 16,2803 Biomedical Research, La Jolla, CA 424,133.1 (US) 2009/0117108 A1 5/2009 Wang et al. 2010/0178276 A1* 7, 2010 Sadelain ............ A61K 39.0011 (*)c Notice:- r Subject to any site- the still 2010/0278830 A1 11/2010 Shoemaker et al. 424,93.7 patent is extended or adjusted under 35 2010, O297076 A1* 11, 2010 Morrison ............. A61K 38,212 U.S.C. 154(b) by 0 days. 424,856 2010/0324008 A1 12/2010 Low et al. (21) Appl. No.: 14/688,894 2012.0034223 A1 2/2012 Hall et al.
    [Show full text]